Annual Information Update

RNS Number : 7302J

Hikma Pharmaceuticals Plc

09 April 2015

 



Hikma Pharmaceuticals PLC

Annual Information Update

London, 9 April 2015.  In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.

 Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date	Headline
09/04/2015	Annual Financial Report
01/04/2015	Hikma Prices debut $500 million five-year eurobond
31/03/2015	Stabilisation Notice
19/03/2015	Fixed income investor meetings
13/03/2015	Director/PDMR Shareholding
11/03/2015	Holding(s) in Company
11/03/2015	Final Results
23/01/2015	Director Declaration
21/01/2015	Notification of major interest in shares
15/01/2015	Blocklisting Interim Review
12/01/2015	Hikma to launch colchicine 0.6mg capsules
07/01/2015	Total Voting Rights
12/11/2014	Director/PDMR Shareholding
11/11/2014	Total Voting Rights
07/11/2014	Notification of major interest in shares
06/11/2014	Directorate Change
06/11/2014	Interim Management Statement
24/10/2014	Hikma announces receipt of Warning Letter from FDA
20/10/2014	Director/PDMR Shareholding
10/10/2014	Statement re Colchicine
10/10/2014	Director/PDMR Shareholding
06/10/2014	Blocklisting Interim Review
06/10/2014	Total Voting Rights
30/09/2014	Regulatory Approval Colchicine
17/09/2014	Acquisition
20/08/2014	Dividend Declaration
20/08/2014	Interim Results
07/08/2014	Notice of Interim Results Announcement
28/07/2014	Director/PDMR Shareholding
24/07/2014	Acquisition
15/07/2014	Acquisition
14/07/2014	Total Voting Rights
27/06/2014	Director/PDMR Shareholding
23/06/2014	Director/PDMR Shareholding
11/06/2014	Director/PDMR Shareholding
10/06/2014	Total Voting Rights
29/05/2014	Director/PDMR Shareholding
29/05/2014	Director/PDMR Shareholding
28/05/2014	Acquisition
27/05/2014	Director/PDMR Shareholding
15/05/2014	Results of AGM
15/04/2014	Interim Management Statement
06/05/2014	Director/PDMR Shareholding
17/04/2014	Annual Information Update

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system.  These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months.  These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date	Document
09/04/2015	Annual Report and Accounts 2014
09/04/2015	Notice of 2015 Annual General Meeting
09/04/2015	Proxy forms for the 2015 Annual General Meeting
10/04/2014	Annual Report and Accounts 2013
10/04/2014	Notice of 2014 Annual General Meeting
10/04/2014	Proxy forms for the 2014 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 

Date Filed	Form	Description
07/04/2015	SH01	Statement of Capital GBP 19,887,933.90
12/12/2014	AP01	Director Appointed Dr. Pamela Josephine Kirby
11/11/2014	SH01	Statement of Capital GBP 19,862,523.90
06/10/2014	SH01	Statement of Capital GBP 19,855,195
08/09/2014	AR01	No Member List
10/06/2014	SH01	Statement of Capital GBP 19,843,04.77
09/06/2014	RES01	Alter Articles 15/05/2014
09/06/2014	MEM/ARTS	Articles of Association
21/05/2014	SH04	Treasury Capital GBP 0
20/05/2014	RES01	Alter Articles 15/05/2014
20/05/2014	AA	Group of Companies' Accounts made up to 31/12/13
15/05/2014	AP01	Director Appointed Mr. Patrick Noel Butler
15/05/2014	TM01	Appointment Terminated, Director Samih Darwazah
15/05/2014	TM01	Appointment Terminated, Director David Rowe Ham
23/04/2014	MR01	Registration of a Charge/ Charge Code 055579340003
07/04/2014	SH01	Statement of Capital GBP 19,815,699.70

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.

Documents provided to Shareholders

Further Information

Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

Peter Speirs

Company Secretary
9 April 2015

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million. 

 

END

 

 

AIUBKLFBEZFFBBZ